Citius Pharmaceuticals, Inc.
Citius Pharmaceuticals, Inc. (CTXR) PE Ratio — Current & Historical Data
Trailing twelve months (TTM) P/E, forward P/E, PEG, and annual PE history — from market prices and filings.
ctxr · pe ratio · data through Sep 30, 2025
Core PE Ratio Metrics
Trailing 12 months · TTMThe price-to-earnings (P/E) ratio for Citius Pharmaceuticals, Inc. (CTXR) measures how much investors pay for each dollar of the company's trailing earnings. CTXR's current PE ratio of N/A is calculated by dividing its stock price of $0.59 by its TTM earnings per share of -$2.06.
Source: FMP · /ratios-ttm · /analyst-estimates · 2025-09-30
PE Ratio History
2011 – 2025 · Annual▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare (Annual)
PE Ratio vs Peers
Biotechnology · 6 peers · Annual PE| Company | Market Cap | PE (Annual) | vs Avg | EPS (TTM) |
|---|---|---|---|---|
Citius Pharmaceuticals, Inc.You CTXR | $7M | N/A | — | -$2.06 |
 Aditxt, Inc. ADTX | $0M | N/A | — | -$1116.70 |
 Apollomics, Inc. APLM | $15M | N/A | — | -$7.57 |
 Athira Pharma, Inc. ATHA | $27M | N/A | — | -$24.70 |
 Curis, Inc. CRIS | $6M | N/A | — | -$0.06 |
 Daré Bioscience, Inc. DARE | $18M | N/A | — | -$0.12 |
 FibroBiologics, Inc. Common Stock FBLG | $2M | N/A | — | -$8.35 |
* N/A — Company is not profitable (TTM) · excluded from industry average · ▸ FMP /stock-peers + /ratios?limit=1 · priceToEarningsRatio
Annual PE Ratio History
| Fiscal Year End | PE Ratio | EPS (TTM) | YoY Change | PE vs Max |
|---|---|---|---|---|
2025-09-30Latest FY2025 | — | $-3.38 | — | |
2024-09-30 FY2024 | — | $-3.38 | — | |
2023-09-30 FY2023 | — | $-3.34 | — | |
2022-09-30 FY2022 | — | $-3.45 | — | |
2021-09-30 FY2021 | — | $-3.19 | — | |
2020-09-30 FY2020 | — | $-6.72 | — | |
2019-09-30 FY2019 | — | $-11.59 | — | |
2018-09-30 FY2018 | — | $-17.52 | — | |
2017-09-30 FY2017 | — | $-28.41 | — | |
2016-09-30 FY2016 | — | $-34.34 | — |
▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare · Zero extra API
About PE Ratio & Methodology
The price-to-earnings (P/E) ratio for Citius Pharmaceuticals, Inc. (CTXR) measures how much investors pay for each dollar of the company's trailing earnings. CTXR's current PE ratio of N/A is calculated by dividing its stock price of $0.59 by its TTM earnings per share of -$2.06.
Frequently asked questions
CTXR pe ratio · 6 questionsCTXR's current PE ratio is N/A as of 2026-06-09, based on a stock price of $0.59 and TTM EPS of -$2.06. Data sourced from Financial Modeling Prep via CTXR's SEC 10-K and 10-Q filings.
▸ Source: FMP · /ratios-ttm · /ratios annual · /analyst-estimates · /stock-peers · Citius Pharmaceuticals, Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: 2026-06-09